

SomnoMed Limited

Q2FY12: +24% device growth; maintain BUY



Wilson HTM
INVESTMENT GROUP

1 February 2012

\$0.95

BUY

Shane Storey PhD MBA
07 3212 1351
shane.storey@wilsonhtm.com.au


Recommendation

SomnoMed grew global device sales volumes +24% in Q2FY12 and lifted its gross margin to 69%. The company appears on track to deliver its guidance of 32,000 device sales and 25% revenue growth in FY12. Our price target is \$1.75 per share after diluting for the acquisition of a Dutch distribution business. We maintain a BUY rating on SomnoMed in view of a 74% TSR. Our positive view on the stock reflects the growing opportunity for oral appliances in the treatment of obstructive sleep apnoea; particularly for mild-moderate disease, where we see a role for low-cost alternatives to CPAP.

Key Points

- **Q2FY12 trading update** – 7,711 units were sold in Q2FY12 (+24% on pcp). Unit growth was 44% in Europe and we estimate 20+% growth in the USA. Record sales achieved in both major territories. Device sales for 1H were in line with our expectations.

Price Performance




Security/Capital Details

ASX Code	SOM
Market Cap	\$40 M
Issued Shares	42.0 M
Avg Mth T'over	0.63 M
12 Mth High – Low	\$1.49 - \$0.91

Key Data/Ratios – FY 2012

EBITDA / Sales	10.3%
EBIT / Sales	8.7%
Net Debt / Equity	-56.9%
Interest Cover	-7.4 x
ROE	21.6%
EPS Growth	64.7%
PEG Ratio	x
NTA / Share	\$ 0.11
DCF	\$ 1.53
12 Mth Price Target	\$ 1.75

Figure 1: Quarterly SomnoDent unit sales FY08-12, by geography



Source: WHTM Research

- **Earnings outlook** – gross margin continued to improve, to 69% for Q2 (67% in Q1). We make small maintenance FY12-13 EPS adjustments but these are not material to our investment view. We are forecasting 17,400 device sales in 2H, which is in line with SomnoMed's FY12 guidance of 32,000. Our revenue forecast of \$15.4m is consistent with company guidance of 25% growth over FY11.
- **Dutch acquisition** – SomnoMed will acquire the Dutch distribution company Goedegebuure Slaaptechniek B. V. (GS) for consideration of c.A\$2.7m, of which c.A\$0.3m has already been paid in cash. The balance will be settled in SOM stock over the next 5 years. Issue prices will be linked to net profit generated by the GS business in Netherlands.
- **Valuation and recommendation** – price target is \$1.75 per share based on DCF. BUY rating maintained with 74% TSR. SomnoMed remains a preferred investment in healthcare given the scope of the growing opportunity for oral appliances in the treatment of obstructive sleep apnoea, established reimbursement in the major markets and their consistent business plan execution.

Year to June	NPAT (Rep) \$M	EPS (Norm) c	EPS Growth %	PER x	P/CF x	EV/EBITDA x	DPS c	Div Yld %	Franking %
2011a	0.7	2.0	-7.0	63.1	-166.7	58.2	0.0	0.0	0
2012e	1.5	3.3	64.7	29.1	21.8	26.5	0.0	0.0	0
2013e	3.3	6.9	112.9	13.7	12.7	11.7	0.0	0.0	0
2014e	4.5	9.4	34.9	10.2	9.5	8.0	0.0	0.0	0

SomnoMed Limited (SOM : \$0.95)

INVESTMENT FUNDAMENTALS

Yr Ending June	2010A	2011A	2012E	2013E	2014E
EPS Reported (c)	2.0	1.8	3.1	6.8	9.2
EPS Normalised (c)	2.1	2.0	3.3	6.9	9.4
EPS Growth (%)	N/A	-7.0%	64.7%	112.9%	34.9%
PER Normalised (x)	39.4	63.1	29.1	13.7	10.2
DPS (c)	0.0	0.0	0.0	0.0	0.0
Payout (%)	0.0%	0.0%	0.0%	0.0%	0.0%
Yield (%)	0.0%	0.0%	0.0%	0.0%	0.0%
Franking (%)	0%	0%	0%	0%	0%

VALUATION DATA

Yr Ending June	2010A	2011A	2012E	2013E	2014E
EV / EBITA (x)	369.8	73.7	29.7	12.4	8.4
EV / EBITDA (x)	160.8	58.2	26.5	11.7	8.0
CFPS (c)	1.2	-0.8	4.4	7.5	10.0
Price / CF	71.8	-166.7	21.8	12.7	9.5
Book Value / Share (\$)	0.1	0.2	0.2	0.2	0.3
Price / Book (x)	6.0	8.1	5.9	4.1	3.0

PROFIT & LOSS (\$m)

Yr Ending June	2010A	2011A	2012E	2013E	2014E
Sales Revenue	10.7	12.3	15.4	20.6	26.3
EBITDA	0.2	0.8	1.6	3.3	4.4
Depreciation	0.1	0.2	0.2	0.2	0.2
EBITA	0.1	0.6	1.4	3.1	4.2
Amortisation	0.1	0.1	0.1	0.1	0.1
EBIT	0.0	0.6	1.3	3.0	4.1
Net Interest Expense	-0.1	-0.1	-0.2	-0.3	-0.4
Pre-tax Profit	0.1	0.7	1.5	3.3	4.5
Tax	-0.7	-0.1	0.0	0.0	0.0
Tax rate (%)	-589.5%	-10.6%	0.0%	0.0%	0.0%
Minorities / pref divs	0.0	0.0	0.0	0.0	0.0
Equity accounted NPAT	0.0	0.0	0.0	0.0	0.0
Net Profit	0.8	0.7	1.5	3.3	4.5
Abn's / Extraord's	0.0	0.0	0.0	0.0	0.0
Reported Net Profit	0.8	0.7	1.5	3.3	4.5
Revenue Growth (%)	N/A	15.1%	24.8%	33.7%	27.6%
EBIT Growth (%)	N/A	2,200.0	133.9%	126.7%	33.4%
NPAT Growth (%)	N/A	-6.0%	106.5%	116.6%	35.6%

PROFITABILITY RATIOS

Yr Ending June	2010A	2011A	2012E	2013E	2014E
EBIT / Sales (%)	0.2%	4.7%	8.7%	14.8%	15.5%
ROA (%)	N/A	13.8%	22.9%	40.0%	44.1%
ROE (%)	N/A	12.4%	21.6%	34.6%	33.4%
ROFE (%)	N/A	34.6%	49.5%	88.4%	103.8%

INTERIMS (\$m)

Half Yr	Dec 10	Jun 11	Dec 11	Jun 12	Dec 12
Yr Ending June	1H A	2H A	1H E	2H E	1H E
Sales Revenue	6.0	6.4	6.8	8.6	9.2
EBIT	0.3	0.3	0.4	0.9	1.2
Net Profit	0.3	0.4	0.5	1.0	1.3
EBIT / Sales (%)	4.4%	4.9%	6.4%	10.6%	13.3%

BALANCE SHEET (\$m)

Yr Ending June	2010A	2011A	2012E	2013E	2014E
Cash	4.3	3.9	4.5	7.5	11.3
Receivables	1.6	2.2	2.7	3.6	4.5
Inventories	0.2	0.2	0.3	0.5	0.6
Other	0.0	0.0	0.0	0.0	0.0
Current Assets	6.1	6.3	7.5	11.5	16.5
Net PPE	0.6	1.1	1.5	1.8	2.3
Investments	0.0	0.0	0.0	0.0	0.0
Intangibles	0.2	0.3	1.5	1.5	1.7
Other	0.8	0.9	1.0	1.0	1.0
Non-current Assets	1.7	2.4	3.9	4.3	5.1
Total Assets	7.8	8.7	11.4	15.8	21.5
Current Payables	1.9	2.2	3.2	4.2	5.4
Current Debt	0.0	0.0	0.0	0.0	0.0
Non-Current Debt	0.0	0.0	0.0	0.0	0.0
Provisions	0.3	0.3	0.3	0.4	0.4
Other	0.0	0.0	0.0	0.0	0.0
Total Liabilities	2.2	2.5	3.6	4.6	5.8
Equity	23.7	24.0	24.2	24.2	24.2
Reserves	1.3	0.8	0.8	0.8	0.8
Retained Profits	-19.4	-18.7	-17.1	-13.8	-9.3
Minorities	0.0	0.0	0.0	0.0	0.0
Total Equity	5.7	6.2	7.9	11.2	15.7
Total Funds Employed	1.4	2.3	3.4	3.7	4.3

LIQUIDITY & LEVERAGE RATIOS

Yr Ending June	2010A	2011A	2012E	2013E	2014E
Net Debt (Cash) (\$m)	-4.3	-4.0	-4.5	-7.5	-11.3
Net Debt / Equity (%)	-75.9%	-63.5%	-56.9%	-67.2%	-72.4%
Interest Cover (x)	-0.3	-6.1	-7.4	-12.0	-9.8
Debt / CashFlow (x)	0.0	0.0	0.0	0.0	0.0

CASHFLOW (\$m)

Yr Ending June	2010A	2011A	2012E	2013E	2014E
EBIT	0.0	0.6	1.3	3.0	4.1
Dep'n and Amort'n	0.2	0.2	0.2	0.3	0.3
Net Int Rec'd (Paid)	0.1	0.1	0.2	0.3	0.4
Tax Paid	0.0	0.0	0.0	0.0	0.0
Dec / (Inc) W'kg Cap	0.1	-0.6	0.5	0.2	0.2
Other	0.0	-0.6	-0.1	-0.1	-0.1
Operating Cash Flow	0.5	-0.3	2.1	3.6	4.9
Capital Expenditure	-0.5	-0.3	-0.4	-0.6	-0.8
Asset Sales	0.0	0.0	0.0	0.0	0.0
Investments	0.0	-0.1	0.0	0.0	0.0
Other Inv. Flows	0.0	0.2	0.0	0.0	0.0
Investing Cash Flow	-0.5	-0.3	-0.4	-0.6	-0.8
Equity Raised	0.4	0.3	0.1	0.0	0.0
Inc / (Dec) in Loans	0.0	0.0	0.0	0.0	0.0
Dividends Paid	0.0	0.0	0.0	0.0	0.0
Other Fin. Flows	0.0	0.0	0.0	0.0	0.0
Financing Cash Flow	0.4	0.4	0.1	0.0	0.0
Net Cash Flow	0.4	-0.2	1.9	3.0	4.1

**Recommendation Structure**

BUY: Total return +10% or more over a 12 month period

HOLD: Total return expected to be between +10% to -10% over a 12-month period

SELL: Total return expected to be -10% or more over a 12 month period

TOTAL RETURN OR TSR = capital growth in share price + expected dividend yield in that period

Other definitions

CS Coverage Suspended. Wilson HTM Ltd has suspended coverage of this company.

NR Not Rated. The recommendation has been suspended temporarily. Such suspension is in line with Wilson HTM Investment Group Ltd policies in circumstances where Wilson HTM Corporate Finance Ltd is acting in an advisory capacity in a merger or strategic transaction involving the company and in certain other situations.

Disclaimer

Whilst Wilson HTM Ltd believes the information contained in this communication is based on reliable information, no warranty is given as to its accuracy and persons relying on this information do so at their own risk. To the extent permitted by law Wilson HTM Ltd disclaims all liability to any person relying on the information contained in this communication in respect of any loss or damage (including consequential loss or damage) however caused, which may be suffered or arise directly or indirectly in respect of such information. Any projections contained in this communication are estimates only. Such projections are subject to market influences and contingent upon matters outside the control of Wilson HTM Ltd and therefore may not be realised in the future.

The advice contained in this document is general advice. It has been prepared without taking account of any person's objectives, financial situation or needs and because of that, any person should, before acting on the advice, consider the appropriateness of the advice, having regard to the client's objectives, financial situation and needs. Those acting upon such information without first consulting one of Wilson HTM Ltd investment advisors do so entirely at their own risk. This report does not constitute an offer or invitation to purchase any securities and should not be relied upon in connection with any contract or commitment whatsoever. If the advice relates to the acquisition, or possible acquisition, of a particular financial product – the client should obtain a Product Disclosure Statement relating to the product and consider the Statement before making any decision about whether to acquire the product. This communication is not to be disclosed in whole or part or used by any other party without Wilson HTM Ltd's prior written consent

Disclosure of Interest. SomnoMed Limited

The Directors of Wilson HTM Ltd advise that at the date of this report they and their associates have relevant interests in SomnoMed Limited. They also advise that Wilson HTM Ltd and Wilson HTM Corporate Finance Ltd A.B.N. 65 057 547 323 and their associates have received and may receive commissions or fees from SomnoMed Limited in relation to advice or dealings in securities. Some or all of Wilson HTM Ltd authorised representatives may be remunerated wholly or partly by way of commission.

In producing research reports, members of Wilson HTM Ltd Research may attend site visits and other meetings hosted by the issuers the subject of its research reports. In some instances the costs of such site visits or meetings may be met in part or in whole by the issuers concerned if Wilson HTM Ltd considers it is appropriate and reasonable in the specific circumstances relating to the site visit or meeting.

BRISBANE

Ph: 07 3212 1333
Fax: 07 3212 1399

SYDNEY

Ph: 02 8247 6600
Fax: 02 8247 6601

MELBOURNE

Ph: 03 9640 3888
Fax: 03 9640 3800

GOLD COAST

Ph: 07 5509 5500
Fax: 07 5509 5599

DALBY

Ph: 07 4660 8000
Fax: 07 4660 4169

HERVEY BAY

Ph: 07 4197 1600
Fax: 07 4197 1699

Our web site: www.wilsonhtm.com.au